Business Context and Reporting Period
Company: Theriva Biologics, Inc. (TOVX)
Filing Type: Form 8-K (Current Report)
Date of Report: October 8, 2025
Event: Presentation of preclinical data for VCN-12, a next-generation oncolytic adenovirus, at the 32nd Annual Congress of the European Society of Gene & Cell Therapy.
Key Financial Metrics
This filing is a Current Report (Form 8-K) regarding a scientific event and does not contain financial statements. The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
No financial material changes are reported. The material event is the advancement of the VCN-X discovery program with the presentation of new preclinical data for VCN-12.
Outlook, Management Commentary, and Risks
- Product Development (VCN-12): VCN-12 utilizes the same capsid as the lead clinical candidate VCN-01 but includes modifications to increase stroma degradation (using bee hyaluronidase) and tumor cell lysis (expressing parasporin-2).
- Preclinical Results:
- In vitro: Increased cell killing compared to VCN-01 across various cancer cell models; higher hyaluronidase activity.
- In vivo (Toxicity): Intravenous administration showed a similar toxicity profile to VCN-01 in immunodeficient mice.
- In vivo (Efficacy): Intratumoral administration significantly reduced tumor growth in immunocompetent hamsters with pancreatic tumors compared to VCN-01.
- Immune Response: Complete tumor regression of the primary tumor was observed in 2 of 9 hamsters. These animals also showed prevention of tumor establishment in secondary implants, suggesting a persistent immune response.
- Future Plans: Further preclinical studies are planned to elaborate on these initial findings.
Investor Verification Checklist
- Verify the full details of the preclinical data presentation filed as Exhibit 99.1.
- Confirm the timeline for the planned further preclinical studies for VCN-12.
- Review the status of the lead clinical candidate, VCN-01 (zabilugene almadenorepvec), to understand the pipeline context.
- Check subsequent filings for any updates on the transition of VCN-12 from preclinical to clinical development.